Clinical Research Prime

1. Pfizer Inc. $4,019,256 275 payments
2. Merck Sharp & Dohme Corporation $1,887,866 46 payments
3. Moderna TX, Inc. $1,412,158 82 payments
4. Sebela Pharmaceuticals Inc. $414,988 23 payments
5. Sanofi US Services Inc. $281,151 13 payments
6. Exeltis, USA Inc. $277,890 34 payments
7. Pacira Pharmaceuticals Incorporated $180,248 15 payments
8. Sanofi Pasteur Inc. $165,025 12 payments
9. Medicines360 $164,977 19 payments
10. Bayer HealthCare Pharmaceuticals Inc. $106,181 15 payments

1. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $1,199,260 51 payments
2. A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants $1,069,310 12 payments
3. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $1,037,373 38 payments
4. A Phase 3 Randomized Openlabel Trial to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine Formulated in Multidose Vials in Healthy Female Adults $867,197 26 payments
5. A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women $501,092 29 payments
6. Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $446,177 25 payments
7. A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability $414,988 23 payments
8. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $413,688 8 payments
9. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $390,585 26 payments
10. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $389,785 8 payments

1. Patient care $45,258 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.